Mirum Pharmaceuticals, Inc. (MIRM) Tops Q1 EPS by 17c
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q1 EPS of ($1.17), $0.17 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $8.46 million.
For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.
